Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Gene Therapy for Sickle Cell Disease—A Debt to Be Paid

Gene Therapy for Sickle Cell Disease—A Debt to Be Paid Opinion EDITORIAL Philip O. Ozuah, MD, PhD Eleven months into the global coronavirus disease 2019 In the US, most patients with SCD have African ancestry, (COVID-19) pandemic that has disproportionately sickened and which can be traced in turn to the United States’ original in- killed people of color and the poor in the US, in this issue of volvement in slavery. Limiting this population’s access to a JAMA Pediatrics DeMartino et al have delivered what amounts cure for a chronic disease that denies them a normal life from to an early warning about childhood on would be a cruel extension of the countless in- what may well be the next justices inflicted on their forebears. It would also be Related article page 617 manifestation of the sys- consistent with the woeful history of SCD treatment in the US. temic disparities that continue to plague health care in the US. While the disease was first described by James B. Herrick in In their assessment of the budget impact and affordability of 1910, the first drug to treat it, hydroxyurea, was not approved a gene therapy for severe sickle cell disease on the 10 state Med- in the US until 1998. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Pediatrics American Medical Association

Gene Therapy for Sickle Cell Disease—A Debt to Be Paid

JAMA Pediatrics , Volume 175 (6) – Jun 22, 2021

Loading next page...
 
/lp/american-medical-association/gene-therapy-for-sickle-cell-disease-a-debt-to-be-paid-Inhf9PhMcQ
Publisher
American Medical Association
Copyright
Copyright 2021 American Medical Association. All Rights Reserved.
ISSN
2168-6203
eISSN
2168-6211
DOI
10.1001/jamapediatrics.2020.7147
Publisher site
See Article on Publisher Site

Abstract

Opinion EDITORIAL Philip O. Ozuah, MD, PhD Eleven months into the global coronavirus disease 2019 In the US, most patients with SCD have African ancestry, (COVID-19) pandemic that has disproportionately sickened and which can be traced in turn to the United States’ original in- killed people of color and the poor in the US, in this issue of volvement in slavery. Limiting this population’s access to a JAMA Pediatrics DeMartino et al have delivered what amounts cure for a chronic disease that denies them a normal life from to an early warning about childhood on would be a cruel extension of the countless in- what may well be the next justices inflicted on their forebears. It would also be Related article page 617 manifestation of the sys- consistent with the woeful history of SCD treatment in the US. temic disparities that continue to plague health care in the US. While the disease was first described by James B. Herrick in In their assessment of the budget impact and affordability of 1910, the first drug to treat it, hydroxyurea, was not approved a gene therapy for severe sickle cell disease on the 10 state Med- in the US until 1998.

Journal

JAMA PediatricsAmerican Medical Association

Published: Jun 22, 2021

References